L
Lisa Rossius
Researcher at Ludwig Maximilian University of Munich
Publications - 3
Citations - 1819
Lisa Rossius is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: FOLFIRI & Cetuximab. The author has an hindex of 3, co-authored 3 publications receiving 1544 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Sebastian Stintzing,Sebastian Stintzing,Dominik Paul Modest,Dominik Paul Modest,Lisa Rossius,Markus M. Lerch,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Markus Moehler,Andreas Jagenburg,Thomas Kirchner,Thomas Kirchner,Andreas Jung,Andreas Jung,Volker Heinemann,Volker Heinemann +27 more
TL;DR: The FIRE-3 trial as discussed by the authors compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRi plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Sebastian Stintzing,Andreas Jung,Lisa Rossius,Dominik Paul Modest,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Salah-Eddin Al-Batran,Ursula Vehling-Kaiser,Tobias Heintges,Markus Moehler,Werner Scheithauer,Thomas Kirchner,Volker Heinemann +13 more
TL;DR: FOLFIRI plus cet as first-line treatment of KRAS WT mCRC patients resulted in comparable overall response rates (ORR) and progression free survival (PFS) when compared to FOLFIRi plus bev.